GlycoMimetics Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- GlycoMimetics's estimated annual revenue is currently $8.4M per year.
- GlycoMimetics received $119.0M in venture funding in March 2018.
- GlycoMimetics's estimated revenue per employee is $153,491
- GlycoMimetics's total funding is $95M.
- GlycoMimetics has 55 Employees.
- GlycoMimetics grew their employee count by -5% last year.
- GlycoMimetics currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Correct Rx Phar...||$16.5M||82||-6%||N/A|
|Factor One Sour...||$7.2M||36||29%||N/A|
What Is GlycoMimetics?
At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow's breakthrough treatments. GlycoMimetics is a clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Since the company's inception in 2003, we have developed a robust, diversified product pipeline. We are a public company traded on the NASDAQ under the symbol GLYC.keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power
Number of Employees
Employee Growth %
|Rachel King||CEO||Email Available|
|John Magnani||Cso, Senior Vp And Co-founder||Email Available|
|Radhika Parikh||Director, Clinical Project Management||Email Available|
|Armand Girard||Senior Vice President, Strategy And Corporate Development||Email Available|
|Scott Shapot||Director, Regulatory Affairs||Email Available|
|Martina Hemmer||Director, Clinical Operations||Email Available|
|Arun Sarkar||Director of Chemistry||Email Available|
|Carol Culwell||Manager of Accounting||Email Available|
|Stephanie Irish||Director, Accounting And Reporting||Email Available|
|David Entin||Director, Corporate Contracts, Licensing And Business Development||Email Available|
UNITED STATES. SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549. SCHEDULE 13G. (Rule 13d-102). INFORMATION ...
The Price to Book ratio for GlycoMimetics, Inc. NasdaqGM:GLYC is 0.841807. The Price to book ratio is the current share price of a company ...
Allianz Asset Management GmbH lowered its stake in shares of GlycoMimetics Inc (NASDAQ:GLYC) by 12.0% during the 2nd quarter, ...
|2003-05-23||$4.3M||1st||New Enterprise Associates||Article|
|2004-08-06||$9.6M||A||Alliance Technology Ventures, Anthem Capital Management||Article|
|2006-06-26||$15.4M||Undisclosed||New Enterprise Associates||Article|
|2009-10-21||$38.0M||Undisclosed||Genzyme Ventures, New Enterprise Associates||Article|
GlycoMimetics Executive Hires
|2012-01-06||Helen Thackray||Chief Medical Officer||Article|
|2014-04-24||Armand Girard||VP Corporate Development||Article|